Deborah Wenkert joined Inozyme in February 2021 and serves as our senior vice president and chief medical officer. She is a leading pediatric rheumatologist with more than 20 years of experience in metabolic bone and genetic disorders, and she will direct Inozyme’s clinical development programs as well as scientific communications activities.

Dr. Wenkert previously served as chief medical officer of PreciThera, Inc., where she managed several early clinical development programs in rare bone diseases. Before that, Dr. Wenkert was a medical director in clinical research at Amgen Inc., where she helped design Phase 2 and lead Phase 3 and 4 clinical trials in the inflammation and  bone therapeutic areas. Both at Amgen and since, she has facilitated multiple regulatory interactions and submissions.

Dr. Wenkert’s career in academic medicine and clinical research includes more than a decade at St. Louis University School of Medicine, where she was an associate adjunct clinical professor of pediatrics. As associate director of the Center for Metabolic Bone Disease and Molecular Research at Shriners Hospital for Children in St. Louis, she conducted research and provided clinical care to children living with metabolic bone and genetic disorders and has volunteered there since.

Dr. Wenkert holds a B.A. in Biochemistry from Rice University, and an M.D. from the University of Texas Medical Branch. She is board-certified in pediatrics and pediatric rheumatology. Dr. Wenkert is the author of more than 35 peer-reviewed research publications, more than 100 scientific conference presentations and has authored two book chapters.